TIB Molbiol Syntheselabor GmbH
Natalie Pauly, PhD, currently serves as the Head of Research and Development at TIB Molbiol Syntheselabor GmbH since March 2021, following a tenure as a Team Lead in Research and Development. Prior to this role, Natalie worked at the Bundesinstitut für Risikobewertung from January 2017 to February 2021, where the focus was on investigating carbapenemase-producing Enterobacteriaceae (CPE) during a PhD thesis, alongside projects analyzing pathogens in plant foods and the prevalence of MRSA in poultry products. Career experience also includes positions as a Technical Assistant, intern roles at the Nationales Referenzlabor and Max Delbrück Center, and conducting a Bachelor thesis at DWI - Leibniz-Institut für Interaktive Materialien. Academically, Natalie earned a PhD in Biomedical Science from Freie Universität Berlin, a Master of Science in Molecular Life Sciences from Humboldt-Universität zu Berlin, and a degree in Biology with a focus on Microbiology and Genetics from RWTH Aachen University.
This person is not in any teams
TIB Molbiol Syntheselabor GmbH
TIB Molbiol is a medium-sized biotech company based out of Berlin, Germany who has supplied the global market for over 30 years with reagents for research and medical diagnostics. We were recently bought by Roche, one of the largest pharma and biotech companies in the world. Roche has committed to keep the start -up character of the company so that the company can benefit from the advantages of a small biotech and the muscle and power of a large pharma/biotech company such as Roche. Our customers are mainly diagnostic and research labs, servicing patients every day, selecting from any of our more than 2,500 diagnostic kits and LightSNiP assays. We fulfill many special orders for custom design of individual assays, for patient need.